Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 5;12(3):e0374923.
doi: 10.1128/spectrum.03749-23. Epub 2024 Feb 12.

Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia

Tatiana Umpeleva  1 , Elena Chetverikova  1 , Danila Belyaev  1   2 , Natalya Eremeeva  1 , Tatiana Boteva  1 , Ludmila Golubeva  1 , Diana Vakhrusheva  1 , Irina Vasilieva  3
Affiliations

Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia

Tatiana Umpeleva et al. Microbiol Spectr. .

Abstract

Collecting data on rare Mycobacterium tuberculosis (Mtb) clinical isolates with resistance to the new anti-tuberculosis drug bedaquiline is an important task for improving antimicrobial susceptibility testing methods. Nanopore whole genome sequencing, the proportion method on Middlebrook 7H11 medium, and BACTEC MGIT 960 assays were used to analyze genotypic and phenotypic resistance to bedaquiline. We found four mutations: atpE I66M, atpE А63Р, Rv0678 А36Т, and Rv0678 S53P in five isolates with different levels of phenotypic bedaquiline resistance.

Importance: Bedaquiline (BDQ) is a new anti-tuberculosis drug. The phenotypic and genotypic data describing the mechanism of drug resistance are critical for the design of rapid and accurate diagnostic tests. We consider that our work, which describes genotypic and phenotypic resistance to BDQ, can contribute to the standardization of drug susceptibility testing.

Keywords: M. tuberculosis; bedaquiline; drug susceptibility testing; mutations; nanopore sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE 9:e102135. doi: 10.1371/journal.pone.0102135 - DOI - PMC - PubMed
    1. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Sci 307:223–227. doi: 10.1126/science.1106753 - DOI - PubMed
    1. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54:1022–1028. doi: 10.1128/AAC.01611-09 - DOI - PMC - PubMed
    1. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979–2981. doi: 10.1128/AAC.00037-14 - DOI - PMC - PubMed
    1. Almeida D, Ioerger T, Tyagi S, Li S-Y, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E. 2016. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:4590–4599. doi: 10.1128/AAC.00753-16 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources